miglustat has been researched along with Fabry Disease in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andreotti, G; Cubellis, MV; Monticelli, M | 1 |
| Etou, Y | 1 |
| Brady, RO | 1 |
| Alp, NJ; Butters, TD; Channon, KM; Clarke, K; Dwek, RA; Heare, T; Kulkarni, AB; Platt, FM; Priestman, DA; Qasba, P | 1 |
| Abe, A; Arend, LJ; Brady, RO; Lee, L; Lingwood, C; Shayman, JA | 1 |
| Abe, A; Brady, RO; Gregory, S; Killen, PD; Kulkarni, A; Lee, L; Shayman, JA | 1 |
2 review(s) available for miglustat and Fabry Disease
| Article | Year |
|---|---|
[Recent therapeutics for Fabry disease].
Topics: 1-Deoxynojirimycin; alpha-Galactosidase; Cell- and Tissue-Based Therapy; Fabry Disease; Genetic Therapy; Glucosamine; Humans; Isoenzymes; Mass Screening; Trihexosylceramides | 2009 |
Emerging strategies for the treatment of hereditary metabolic storage disorders.
Topics: 1-Deoxynojirimycin; Bone Marrow Transplantation; Enzyme Inhibitors; Fabry Disease; Gangliosidosis, GM1; Gaucher Disease; Genetic Therapy; Humans; Imino Sugars; Piperidines | 2006 |
4 other study(ies) available for miglustat and Fabry Disease
| Article | Year |
|---|---|
Looking for protein stabilizing drugs with thermal shift assay.
Topics: 1-Deoxynojirimycin; alpha-Galactosidase; Drug Evaluation, Preclinical; Enzyme Stability; Fabry Disease; Glycogen Storage Disease Type II; High-Throughput Screening Assays; Humans; Temperature | 2015 |
Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment.
Topics: 1-Deoxynojirimycin; alpha-Galactosidase; Animals; Aorta; Disease Models, Animal; Enzyme Inhibitors; Fabry Disease; Female; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Microscopy, Electron; Phenotype | 2007 |
Glycosphingolipid depletion in fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase.
Topics: 1-Deoxynojirimycin; alpha-Galactosidase; B-Lymphocytes; Bacterial Toxins; Cell Line, Transformed; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fabry Disease; Fluorescein-5-isothiocyanate; Fluorescent Dyes; Genetic Vectors; Glucosyltransferases; Glycosphingolipids; Herpesvirus 4, Human; Humans; Neutral Glycosphingolipids; Propanolamines; Pyrrolidines; Shiga Toxin 1; Trihexosylceramides | 2000 |
Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation.
Topics: 1-Deoxynojirimycin; Animals; Dose-Response Relationship, Drug; Fabry Disease; Kidney; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Propanolamines; Pyrrolidines; Trihexosylceramides | 2000 |